Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.

Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, Tei M, Kochi M, Manaka D, Ohori H, Yamaguchi T, Sagawa T, Kotaka M, Kubota Y, Sekikawa T, Nakamura M, Takeuchi M, Ichikawa W, Fujii M, Tsuji A

Open source

DOI: 10.1038/s41467-024-54460-2
Published: 2024 Nov 25
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-024-54460-2,
  title = {Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.},
  author = {Shiozawa M and Sunakawa Y and Watanabe T and Ota H and Yasui H and Yabuno T and Tei M and Kochi M and Manaka D and Ohori H and Yamaguchi T and Sagawa T and Kotaka M and Kubota Y and Sekikawa T and Nakamura M and Takeuchi M and Ichikawa W and Fujii M and Tsuji A},
  year = {2024},
  journal = {Nature communications},
  doi = {10.1038/s41467-024-54460-2},
  url = {https://doi.org/10.1038/s41467-024-54460-2}
}

RIS

TY  - JOUR
TI  - Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.
AU  - Shiozawa M
AU  - Sunakawa Y
AU  - Watanabe T
AU  - Ota H
AU  - Yasui H
AU  - Yabuno T
AU  - Tei M
AU  - Kochi M
AU  - Manaka D
AU  - Ohori H
AU  - Yamaguchi T
AU  - Sagawa T
AU  - Kotaka M
AU  - Kubota Y
AU  - Sekikawa T
AU  - Nakamura M
AU  - Takeuchi M
AU  - Ichikawa W
AU  - Fujii M
AU  - Tsuji A
PY  - 2024
JO  - Nature communications
DO  - 10.1038/s41467-024-54460-2
UR  - https://doi.org/10.1038/s41467-024-54460-2
ER  -

APA

M, S., Y, S., T, W., H, O., H, Y., T, Y., M, T., M, K., D, M., H, O., T, Y., T, S., M, K., Y, K., T, S., M, N., M, T., W, I., M, F., & A, T. (2024). Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.. Nature communications. https://doi.org/10.1038/s41467-024-54460-2

Source records

pubmed · retrieved 2026-09-26T22:47:40.204Z
europe-pmc · retrieved 2026-09-26T22:47:40.220Z
doaj · retrieved 2026-09-26T22:47:40.215Z